Mon, Dec 22, 2014
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
Industry Updates

Parker FX Index is up +0.82% in July (-0.57% YTD)

Friday, August 29, 2014
Opalesque Industry Update - The Parker FX Index is reporting a +0.82% return for the month of July. Thirty-two of the thirty-six programs in the Index reported July results, of which nineteen reported positive results and thirteen incurred losses. On a risk-adjusted basis, the Index was up +0.36% in July. The median return for the month was +0.24%, while the performance for July ranged from a high of +7.32% to a low of -2.50%.

In addition to the broad Parker FX Index, there are two style driven sub-indices: the Parker Systematic Index, which tracks those managers whose decision process is rule based, and the Parker Discretionary Index, which tracks managers whose decision process is judgmental. During July, the Systematic Index was up +0.54% and the Discretionary Index was up +1.10%. On a risk-adjusted basis, the Parker Systematic Index was up +0.20% and the Parker Discretionary Index was up +0.83%.

The top three performing constituent programs for the month of July on a reported basis returned +7.32%, +5.71% and +4.93%, respectively. The top three performers on a risk-adjusted basis returned +3.05%, +2.42% and +2.09%, respectively.

The US dollar rose in July on improved economic data as US growth for Q2 accelerated. The euro saw continuing weakness after June’s rate cut and the potential effects on growth as a result of the conflict between Ukraine and Russia and its subsequent sanctions. Looking ahead, managers believe that the market is looking favorable for the USD, but also see potential for a weaker growth outlook in Europe and a number of emerging markets due to the situation between Russia and Ukraine.
PD

What do you think?

   Use "anonymous" as my name    |   Alert me via email on new comments   |   
Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing


  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. Investing - Big hedge funds win again on PetSmart, Riverbed, RBS sells real estate loans to hedge fund Cerberus, Talisman energy speculation: Which hedge funds could benefit?[more]

    Big hedge funds win again on PetSmart, Riverbed From CNBC.com: Another week, another set of wins for activist investors. On Sunday, pet supply retailer PetSmart agreed to the largest leveraged buyout of the year at $8.7 billion. Hedge fund firm JANA Partners had been pushing for a sale a

  2. Outlook - Hedge fund manager who remembers 1998 rout says prepare for pain, Bond guru Bill Gross predicts U.S. economic growth to dip to 2%[more]

    Hedge fund manager who remembers 1998 rout says prepare for pain From Bloomberg.com: Stephen Jen landed in Hong Kong in early January 1997 as Morgan Stanley’s newly minted exchange-rate strategist for Asia. He was soon working around the clock when investors began targeting the region’s

  3. Investing - Hedge funds get boost from healthcare in 2014, Paulson & Co takes stake in Salix on heels of inventory issues[more]

    Hedge funds get boost from healthcare in 2014 From Valuewalk.com: The healthcare sector started the year on a turbulent note, as stocks of many major biotechnology companies were battered. However, most of the players in this sector have bounced back. The BarclayHedge Healthcare & Biotec

  4. North America - Why Steve Cohen, Connecticut hedge fund billionaire, gives so much in New York[more]

    From Insidephilantrophy.com: Billionaire Steve Cohen was born in Great Neck, New York before attending Wharton, working on Wall Street and then founding SAC Capital Advisors in Connecticut. Though his company (Point72) and foundation are based in Connecticut, Cohen and Alexandra are deeply connected

  5. Investing - Soros buys a highly speculative biotech in the third quarter[more]

    From Fool.com: …The Soros Fund bought 25,000 shares of the struggling small-cap biopharma Aegerion Pharmaceuticals in the third quarter. For those of you who haven't heard of this name, suffice to say that this was a surprising buy in light of the company's recent problems and poor outlook going for